Tuesday, April 25, 2023
Boehringer Ingelheim inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riß, Germany.
The new high-tech facility underlines the company’s strong commitment to Germany and Europe as location for research and development (R&D) for the care of patients around the world. With the investment of 350 million EUR, Boehringer Ingelheim significantly enhances its innovation power and development of biopharmaceutical development capabilities in Germany.
The new facility is a highly complex building, offering modern workplaces for more than 500 employees who will develop Boehringer Ingelheim's future biopharmaceutical substances. Scientists from multiple disciplines and three different development units will collaborate under one roof to research and develop antibodies and therapeutic proteins.
The BDC is a building with a gross floor space of 34,500 sqm, which equals five football fields. The construction of the BDC is part of Boehringer Ingelheim's consistent future strategy with significant investments in its R&D pipeline, which amounted to 5 billion EUR in the last business year – 47 per cent alone in Germany.
